A review of Perindopril in the reduction of cardiovascular events

Duncan J CampbellSt. Vincent’s Institute of Medical Research and the Department of Medicine, University of Melbourne, St. Vincent’s Hospital, Fitzroy, Victoria, AustraliaBackground: Angiotensin-converting enzyme inhibitors (ACEI) have a well-established role in the prevention of...

Full description

Bibliographic Details
Main Author: Duncan J Campbell
Format: Article
Language:English
Published: Dove Medical Press 2006-06-01
Series:Vascular Health and Risk Management
Online Access:https://www.dovepress.com/a-review-of-perindopril-in-the-reduction-of-cardiovascular-events-peer-reviewed-article-VHRM
id doaj-239c7b1d372847ca9568f4c888a8bccf
record_format Article
spelling doaj-239c7b1d372847ca9568f4c888a8bccf2020-11-24T22:14:43ZengDove Medical PressVascular Health and Risk Management1178-20482006-06-01Volume 21171241410A review of Perindopril in the reduction of cardiovascular eventsDuncan J CampbellDuncan J CampbellSt. Vincent’s Institute of Medical Research and the Department of Medicine, University of Melbourne, St. Vincent’s Hospital, Fitzroy, Victoria, AustraliaBackground: Angiotensin-converting enzyme inhibitors (ACEI) have a well-established role in the prevention of cardiovascular events in hypertension, left ventricular dysfunction, and heart failure. More recently, ACEI have been shown to prevent cardiovascular events in individuals with increased cardiovascular risk, where hypertension, left ventricular dysfunction, or heart failure was not the primary indication for ACEI therapy.Objective: To review studies of the effects of the ACEI perindopril on cardiovascular events.Method: The EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease Study), PROGRESS (Perindopril Protection Against Recurrent Stroke Study), and ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm) trials are reviewed.Results: Perindopril alone reduced cardiovascular events in subjects with stable coronary heart disease. Perindopril in combination with indapamide reduced cardiovascular events in subjects with cerebrovascular disease. Perindopril in combination with amlodipine reduced cardiovascular events in subjects with hypertension.Conclusion: Perindopril reduced cardiovascular events. The reduction of cardiovascular events by perindopril was in large part associated with reduction of blood pressure, and greater reduction in cardiovascular events was associated with greater reduction of blood pressure. Perindopril may need to be combined with other antihypertensive agents to maximize reduction of cardiovascular events.Keywords: Angiotensin-converting enzyme inhibitor, hypertension, coronary heart disease, stroke, myocardial infarction, heart failurehttps://www.dovepress.com/a-review-of-perindopril-in-the-reduction-of-cardiovascular-events-peer-reviewed-article-VHRM
collection DOAJ
language English
format Article
sources DOAJ
author Duncan J Campbell
spellingShingle Duncan J Campbell
A review of Perindopril in the reduction of cardiovascular events
Vascular Health and Risk Management
author_facet Duncan J Campbell
author_sort Duncan J Campbell
title A review of Perindopril in the reduction of cardiovascular events
title_short A review of Perindopril in the reduction of cardiovascular events
title_full A review of Perindopril in the reduction of cardiovascular events
title_fullStr A review of Perindopril in the reduction of cardiovascular events
title_full_unstemmed A review of Perindopril in the reduction of cardiovascular events
title_sort review of perindopril in the reduction of cardiovascular events
publisher Dove Medical Press
series Vascular Health and Risk Management
issn 1178-2048
publishDate 2006-06-01
description Duncan J CampbellSt. Vincent’s Institute of Medical Research and the Department of Medicine, University of Melbourne, St. Vincent’s Hospital, Fitzroy, Victoria, AustraliaBackground: Angiotensin-converting enzyme inhibitors (ACEI) have a well-established role in the prevention of cardiovascular events in hypertension, left ventricular dysfunction, and heart failure. More recently, ACEI have been shown to prevent cardiovascular events in individuals with increased cardiovascular risk, where hypertension, left ventricular dysfunction, or heart failure was not the primary indication for ACEI therapy.Objective: To review studies of the effects of the ACEI perindopril on cardiovascular events.Method: The EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease Study), PROGRESS (Perindopril Protection Against Recurrent Stroke Study), and ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm) trials are reviewed.Results: Perindopril alone reduced cardiovascular events in subjects with stable coronary heart disease. Perindopril in combination with indapamide reduced cardiovascular events in subjects with cerebrovascular disease. Perindopril in combination with amlodipine reduced cardiovascular events in subjects with hypertension.Conclusion: Perindopril reduced cardiovascular events. The reduction of cardiovascular events by perindopril was in large part associated with reduction of blood pressure, and greater reduction in cardiovascular events was associated with greater reduction of blood pressure. Perindopril may need to be combined with other antihypertensive agents to maximize reduction of cardiovascular events.Keywords: Angiotensin-converting enzyme inhibitor, hypertension, coronary heart disease, stroke, myocardial infarction, heart failure
url https://www.dovepress.com/a-review-of-perindopril-in-the-reduction-of-cardiovascular-events-peer-reviewed-article-VHRM
work_keys_str_mv AT duncanjcampbell areviewofperindoprilinthereductionofcardiovascularevents
AT duncanjcampbell reviewofperindoprilinthereductionofcardiovascularevents
_version_ 1725797464908234752